Back to Blog

Continuation Patents: When and How to File

April 26, 2026 Aruna 15 min read

This guide covers the mechanics: what a continuation is, the deadlines that keep a family alive, and the double-patenting law that decides whether the extra patents survive. For the portfolio-level question of which continuations are worth filing in the first place, see our dedicated playbook on patent continuation strategy.

continuation application — intellectual property law and protection

A continuation patent application is one of the most powerful tools in a sophisticated patent portfolio strategy. Continuations allow you to pursue additional claims based on an already-pending or recently granted patent application, creating a family of related patents that provide layered protection for your invention. At PerspireIP, we regularly use continuation patent applications to build robust IP portfolios for our clients. This guide explains the different types of continuations, when to use them, and how to file them effectively.

What Is a Continuation Patent Application?

A continuation application is a new patent application that claims priority to a previously filed parent application and uses the same specification (written description) as the parent. The continuation must be filed while the parent application is still pending — before it issues as a patent or goes abandoned. Continuation applications share the parent’s filing date for prior art purposes, giving you the full benefit of your original filing date for any claims you pursue in the continuation.

Continuation applications do not extend the patent term. Both the parent patent and all continuation patents in the family expire 20 years from the earliest effective filing date of the parent application. However, within that 20-year window, you can pursue different claim sets that provide complementary protection.

Types of Continuation Applications

There are three main types of continuation applications, each with distinct purposes and requirements.

Continuation (CON)

A straight continuation uses the same specification as the parent without any new subject matter. It allows you to pursue claims that are different from — but fully supported by — the original disclosure. Continuations are used to pursue broader claims that were not previously examined, claims in different formats (method vs. apparatus), or claims directed to different aspects of the disclosed invention.

Continuation-in-Part (CIP)

A continuation-in-part includes the specification of the parent application plus new subject matter. CIPs are used when you have made improvements or modifications to your original invention that you want to add to the specification. However, only claims directed to subject matter fully disclosed in the parent application benefit from the parent’s filing date. Claims that require the new subject matter have an effective priority date of the CIP filing date — an important distinction for prior art purposes.

Divisional Application (DIV)

A divisional application is filed when the USPTO issues a restriction requirement — a determination that your original application contains claims directed to more than one independent and distinct invention and that you must elect one group of claims for examination. A divisional allows you to pursue the non-elected claims in a separate application while maintaining the parent’s filing date. Divisionals are not elective — they arise from a specific USPTO procedural step.

Strategic Reasons to File Continuation Patent Applications

Sophisticated patent filers use continuation patent applications for a variety of strategic purposes beyond simply pursuing additional claims.

  • Responding to competitor products: if a competitor introduces a new product after your original filing date, you can file a continuation with claims specifically tailored to cover that product while maintaining your original priority date.
  • Pursuing broader claims: after a narrow patent issues, you may file a continuation to pursue broader claims that the examiner might allow now that the narrower version is on record.
  • Building blocking positions: a family of continuation patents with overlapping but different claims creates a comprehensive IP barrier that is much harder for competitors to design around.
  • Preserving prosecution flexibility: keeping a continuation application pending maintains your ability to respond to market developments with new claims for years into the future.
  • Licensing leverage: a family of patents with different claim scopes provides more licensing options and stronger negotiating positions.

The Evergreen Portfolio Strategy

One of the most effective uses of continuation applications is the evergreen portfolio strategy, where a patentee keeps at least one continuation application pending in each technology area at all times. This ensures that when a competitor introduces a new product or technology, you have a pending application that can be amended to claim it, assuming your original specification supports such claims. This strategy has been used effectively by companies such as Qualcomm and InterDigital to build licensing programs worth billions of dollars.

Evergreening is only one expression of a broader patent continuation strategy. The decision that actually matters is sequencing: which claims to pursue now, which to hold back for a continuation filed before the parent issues, and which to abandon rather than pay to prosecute twice. A deliberate patent continuation strategy ties each filing to a commercial trigger — a competitor launch, a licensing negotiation, a funding round — instead of filing continuations reflexively whenever a parent approaches allowance.

How to File a Continuation Patent Application

Filing a continuation patent application requires attention to specific procedural requirements. The continuation must be filed before the parent application issues as a patent or goes abandoned — the day the parent issues, it is too late to file a continuation. The continuation must contain a specific claim of priority to the parent application, identifying the parent’s application number and filing date. The claim of priority must be made in the application data sheet filed with the continuation. The continuation uses the parent’s specification but must include new formal drawings if any figures are added, and must include at least one claim.

Continuation Applications and Patent Term

While continuation applications do not extend patent term beyond the parent’s 20-year term, patent term adjustments (PTAs) can add days to individual patents based on USPTO delays during prosecution. Each continuation is examined independently and may receive its own PTA, but the PTA is calculated based on the continuation’s own prosecution history, not the parent’s. Understanding the interaction between continuation strategies and patent term is important for long-range portfolio planning.

Building the Chain: Scope Decisions Before Filing

A continuation is a filing mechanism. A continuation plan is a decision about claim scope made years before you know which claims will matter. The two are often confused, and the confusion is expensive: firms file continuations reflexively at every notice of allowance without deciding what the new claims are supposed to cover, then discover at enforcement that the family protects the embodiment they shipped in 2022 and nothing a competitor sells today.

The discipline that separates a working plan from a reflex is claim laddering.

The first patent in a family should be the one you can get quickly — a narrow, clearly allowable claim set that gives you an issued asset, a marking right and a credible threat. Each continuation then climbs or widens: one targeting the broadest language the specification will support, one drafted around the architecture a competitor appears to be heading toward, one written as a method claim where the original was an apparatus claim, one covering the component you expect to be sold separately.

The Federal Circuit has long accepted that it is legitimate to draft continuation claims with a competitor’s product in view, provided the original specification already supports them — which is precisely the constraint that makes the strategy a drafting problem rather than a filing problem.

That constraint, 35 U.S.C. § 112(a) written description, is where most late-drafted claims fail. You cannot claim in 2026 what the 2019 specification never described. The practical implication runs backwards through the whole process: the value of a continuation chain is set by how much optionality the original application captured. Specifications drafted with alternative embodiments, ranges, substitutable components and genuinely different levels of generality support a decade of continuations. A tightly written specification describing one product does not, no matter how many applications you file off it.

It is also worth being clear about what a continuation is not. A request for continued examination under 37 CFR 1.114 reopens prosecution in the same application — same serial number, same term, no new family member. It is the right tool when you simply need another round with the examiner on the claims you already have. A continuation under 37 CFR 1.53(b) creates a new application with its own serial number, its own examination, and its own patent term adjustment clock. Choosing the RCE because it is cheaper, when what you actually wanted was a second asset with different claims, is one of the more common and least reversible mistakes in this area.

Deadlines That Keep the Chain Alive

Every benefit claim in the family rests on copendency. Section 120 gives a later application the earlier filing date only if it is filed before the patenting, abandonment, or termination of proceedings on the parent. Miss that window by a day and the chain breaks: the new application stands on its own filing date, and the parent — now published — becomes prior art against it. There is no fee that fixes this and no routine petition that restores it.

The window closes at the parent’s issue date, not at the notice of allowance, which is what makes the allowance the real decision point. Once the issue fee is paid the clock is short and the choice to continue has to already be made. Teams that run this well treat every notice of allowance as a scheduled decision with a named owner: continue, or deliberately close the family. Teams that do not run it well discover the question only when the parent has already issued.

Two paperwork requirements then decide whether the benefit claim is actually perfected. The reference to the prior application must appear in an application data sheet, and under 37 CFR 1.78 it must be submitted within the later of four months from the child’s actual filing date or sixteen months from the prior application’s filing date. A late or omitted benefit claim is recoverable by petition on a showing that the delay was unintentional, but petitions cost time and money and occasionally fail, so the ADS entry belongs in the filing checklist rather than in the clean-up queue.

Term is the other clock, and it does not restart. Under § 154(a)(2) the twenty-year term runs from the earliest non-provisional filing date in the chain, so a continuation filed in year eight yields a patent with roughly twelve years of life. That arithmetic should shape how long a family is kept open: a continuation filed late in the term can still be commercially decisive if it reads on a competitor’s current product, but it is a poor instrument for ordinary portfolio padding, and the examination cost is the same either way.

What a Continuation Chain Actually Costs

Most continuation guidance stops at strategy and never prices it. Every continuation application is a new application in its own right, so it pays the full large-entity filing, search, and examination fees — $350, $770, and $880, or $2,000 together — each time you file one. Claiming benefit under 35 U.S.C. § 120 discounts none of that. Small and micro entities pay reduced rates, but the structure is identical. A patent continuation strategy that assumes the parent’s fees carry forward will be short by roughly two thousand dollars per link in the chain before a single office action arrives.

The bigger surprise is the continuing-application surcharge the USPTO introduced in its January 2025 fee setting. File a continuation, or present a benefit claim, more than six years after the earliest benefit date and a $2,700 surcharge attaches (fee code 1055). Push past nine years and it becomes $4,000 (fee code 1056). These are additive to the $2,000 in basic fees, not a replacement for them. The date that governs is the earliest benefit date in the chain, not the immediate parent’s filing date, so a long evergreen chain grows steadily more expensive the further it runs from its own priority anchor.

Requests for continued examination escalate in the same way. The first RCE in an application costs $1,500; the second and every one after it costs $2,860. Teams often reach for an RCE when a continuation would serve them better, or the reverse, without ever comparing the two prices. An RCE keeps you inside the same application and preserves its term, while a continuation application starts a fresh examination and a fresh set of basic fees. Pricing both options at the moment of a final rejection is a two-minute exercise that routinely changes the answer.

None of these figures include attorney time, which usually dominates the bill. But the fee schedule alone explains why late-chain filings deserve more scrutiny than early ones. A continuation filed in year three carries $2,000 in government fees. The same filing in year ten carries $6,000 before anyone drafts a claim. That gap is wide enough to change which embodiments are worth protecting and which should simply be abandoned.

Budgeting a Continuation Strategy Across a 20-Year Term

Because the surcharges key off the earliest benefit date, the cost of a chain is a function of calendar time rather than of how many applications you have filed. Two portfolios with five continuations each can differ by more than ten thousand dollars in government fees purely on the basis of when those filings landed. The practical consequence is that the inexpensive window for a continuation strategy is the first six years after the priority date, and the window after year nine is the costly one.

That argues for front-loading. Where the specification already supports claims you expect to want, filing those continuation applications inside the six-year window costs $2,000 each instead of carrying $4,000 in surcharge later. The counterargument is a real one: filing early means guessing which claims will matter before the market or the competition has revealed itself. The usual resolution is to file early where the parent’s disclosure clearly supports a distinct commercial embodiment, and to reserve late filings for claims that genuinely respond to something new.

Copendency remains the hard constraint underneath all of this. A continuation must be filed while its parent is still pending, so a chain that has lapsed cannot be revived by paying a surcharge. Budget discussions that look only at fees sometimes lose sight of that: the cheapest continuation is worthless if the docket let the parent issue first. Fee planning and deadline discipline are therefore the same exercise, which is why both belong on one docket rather than in a spreadsheet kept alongside it.

A workable rule of thumb is to price every continuation decision against the earliest benefit date, never the filing date of its immediate parent, and to re-check the number at the six-year and nine-year marks. Those two dates are the only points where the arithmetic shifts sharply, and both are predictable years in advance. Putting them on the docket as cost events, and not merely as legal deadlines, is what keeps a continuation strategy from quietly doubling in price.

Where a Continuation Strategy Backfires

Obviousness-type double patenting is the first and most common failure mode. It is a judicially created doctrine rather than a statutory one, and it bars a second patent whose claims are not patentably distinct from an earlier family member’s. The usual cure is a terminal disclaimer under 37 CFR 1.321(c), which caps the later patent’s term at the earlier one’s expiry and ties its enforceability to common ownership — a cost that is trivial on the day you file it and significant on the day you want to sell or license one patent out of the family separately.

Recent case law has made that calculation sharper. In In re Cellect (Fed. Cir. 2023) the court held that the double patenting comparison uses expiration dates as adjusted by patent term adjustment, so a parent that earned substantial PTA can be invalidated by reference to a family member that expires earlier — term you were awarded for the Office’s own delay turned into an invalidity exposure.

Allergan v. MSN Laboratories (Fed. Cir. 2024) pulled in the other direction, holding that a first-filed, first-issued claim cannot be invalidated for double patenting by a later-filed, later-issued continuation in the same family. Read together, the order in which a family is filed and allowed now carries real consequences, which is an argument for deciding the shape of the whole chain early rather than improvising at each allowance.

Two further risks deserve a place on the checklist. Narrowing amendments made anywhere in the chain surrender equivalents for the amended element, so a continuation drafted to recapture scope given up during the parent’s prosecution may be unenforceable against the very design the amendment excluded. And in Hyatt v. Hirshfeld (Fed. Cir. 2021) the court confirmed that prosecution laches remains available against applicants who keep a family pending for an unreasonable and unexplained period — a doctrine aimed at decades-long chains rather than ordinary practice, but a reminder that an open family is not a free option.

None of this argues against continuations. It argues for treating the chain as a designed structure with a stated purpose for each link, a named decision owner at every allowance, and a documented reason to close the family when the claims worth pursuing run out. That is the difference between a patent continuation strategy and a standing instruction to keep filing.

How PerspireIP Manages Continuation Strategies

At PerspireIP, we develop continuation strategies as part of a comprehensive IP plan for each client. We monitor pending applications and issued patents in the family, identify opportunities to file continuations that address competitor products or market developments, and draft continuation claims that maximize coverage while remaining fully supported by the original specification. We also track critical deadlines to ensure continuation rights are never inadvertently forfeited.

Conclusion

Continuation patent applications are a cornerstone of sophisticated patent portfolio management. By strategically filing continuations, divisionals, and continuation-in-parts, you can build a family of patents that provides comprehensive, layered protection for your invention over many years. PerspireIP has the expertise and experience to help you develop and execute a continuation strategy that maximizes the value of your patent portfolio. Contact us today to discuss your continuation opportunities.